Two out of four patients with no mutations via NGS at diagnosis showed other AML genetic drivers (one patient 6; 11 translocations associated to a germinal BRCA2 mutation and one patient DEK-NUP214 translocation), whereas the other two patients only had WT1 overexpression. This evidence concerns the gene BRCA2 and acute myeloid leukemia.